Baili Tianheng (688506.SH): GNC-077 monoclonal antibody injection for the treatment of advanced solid tumors has obtained the Phase I clinical trial approval notification.

Baoli Tianheng (688506.SH) announced that the company recently received the official approval letter for the clinical trial of the company's independently developed innovative biopharmaceutical GNC-077 from the National Medical Products Administration (NMPA). According to the "Drug Administration Law of the People's Republic of China" and relevant regulations, the clinical trial application for GNC-077 multi-specific antibody injection, which was accepted on July 16, 2024, meets the relevant requirements for drug registration, and the company has been authorized to conduct clinical trials for late-stage solid tumors.